Eurofins Genoma GeneSafe

Eurofins Genoma has introduced GeneSafe, a non-invasive prenatal test that screens for both de novo and inherited single-gene disorders. Current commercial NIPTs only screen for aneuploidies and microdeletions, the firm said. GeneSafe identifies fetal conditions that could be missed by traditional prenatal testing, detecting more than 40 severe genetic disorders that may occur in the absence of a family history of the condition. The company said it also detects disorders with an increased prevalence associated with advanced paternal age. The test requires a small blood sample and has a turnaround time of 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder, the company noted.